Researchers from Hefei Industrial Pharmaceutical Institute Co. Ltd. presented the discovery and preclinical evaluation of novel multifunctional inhibitors as potential anti-inflammatory and analgesic agents.
Researchers from Wenzhou Medical University and affiliated organizations have reported the discovery and preclinical evaluation of novel anti-inflammatory compounds. Synthesis and optimization of a new series of 1-(4-(benzylsulfonyl)-2-nitrophenyl) derivatives resulted in the identification of compound [I] as the lead candidate.
UCB SA has identified imidazotriazine derivatives acting as IL-17 modulators reported to be useful for the treatment of autoimmune and inflammatory disorders.
Researchers from Meiji Seika Pharma Co. Ltd. and affiliated organizations reported the discovery and preclinical evaluation of a novel PD-1 agonist antibody, HM-266, being developed for the treatment of various inflammatory disorders, including autoimmune diseases.
Reservoir Neuroscience Inc. has disclosed prostaglandin E2 receptor EP2 subtype (PTGER2; EP2) antagonists reported to be useful for the treatment of inflammation.
University of Copenhagen has divulged 4-hydroxypyridine and 4-hydroxyquinoline derivatives acting as G-protein coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of fibrosis, diabetes, inflammatory and cognitive disorders.
Cantargia AB has completed a GLP toxicity study for its anti-inflammatory IL1RAP-binding antibody CAN-10, showing that CAN-10 was well tolerated when administered over 6 weeks.
Ono Pharmaceutical Co. Ltd. has entered an option and research collaboration agreement with Monash University to discover and develop antibodies targeting G protein-coupled receptors (GPCRs) with the aim of creating novel therapeutics for the treatment of autoimmune and inflammatory diseases.
An Icelandic genome-wide association study that linked variants in a gene which regulates retinoic acid synthesis to severe osteoarthritis (OA) of the hands, has led on to the discovery of an anti-inflammatory role for the vitamin A metabolite and pointed to a new class of potentially disease-modifying drugs. A proof-of-concept clinical trial of talarozole, a retinoic acid metabolism blocking agent, is now taking place to assess if increasing retinoic acid production suppresses inflammation in the joint tissues of patients with OA.
RSS
